Supplementary figure 1. Phenotype of V\textsubscript{H}1-69\textsuperscript{+} B cells in patient 1 (a) before and (b) 26 months after therapy. Dot plots illustrate the frequency of V\textsubscript{H}1-69\textsuperscript{+} B cells among total B cells and the frequency of CD21\textsuperscript{low} B cells among V\textsubscript{H}1-69\textsuperscript{+} B cells. Histograms illustrate the expression of CD95 and CD86 in CD21\textsuperscript{high} B cells (gray histograms) and CD21\textsuperscript{low} B cells (open histograms). Expression of CD95 and CD86 by CD21\textsuperscript{low} B cells at month 26 after therapy could not be adequately investigated because of the paucity of these cells.

Supplementary figure 2. Phenotype of V\textsubscript{H}1-69\textsuperscript{+} B cells in patient 3 (a) before and (b) one month after termination of therapy. Dot plots illustrate the frequency of V\textsubscript{H}1-69\textsuperscript{+} B cells among total B cells and the frequency of CD21\textsuperscript{low} and CD11c\textsuperscript{+} V\textsubscript{H}1-69\textsuperscript{+} B cells; the CD11c\textsuperscript{+} cell population includes only CD21\textsuperscript{low} cells (not shown).